Reinfusion of autologous hematopoietic peripheral blood stem cells (PBSC) or bone marrow is often accompanied by flushing, dyspnea, abdominal cramping, nausea and diarrhea. These symptoms and the observation that they can be prevented by ondansetron, a selective 5-HT 3 receptor antagonist, led to the assumption that these side-effects are due to infusion of free serotonin during the reinfusion of PBSC or bone marrow. Twenty-five patients with solid tumors received, after myeloblative chemotherapy, a total of 30 reinfusions of PBSC and/or bone marrow. In 17 patients, serotonin levels in the bags containing the PBSC were measured. In all patients, platelet serotonin levels were determined before and 1 h post-reinfusion. In addition, before and 24 h after reinfusion urine was collected for determination of 5-hydroxyindole acetic acid (5-HIAA) and serotonin concentrations. Mean (± s.d.) total serotonin concentration in the bags was 2404 ± 1555 nmol/l. Mean total volume reinfused was 471 ± 185 ml. After reinfusion, the mean (± s.d.) levels of serotonin in platelets in patients increased from 3.2 ± 1.4 nm/10 9 at baseline to 3.8 ± 2.0 nm/10 9 (P = 0.02). Neither 24 h urinary 5-HIAA nor serotonin levels were affected. These results indicate that reinfusion of PBSC or bone marrow is accompanied by substantial infusion of free serotonin, which might explain the observed side-effects and justify the use of 5-HT 3 receptor antagonists as premedication for this procedure. Keywords: serotonin; peripheral stem cell reinfusion; side-effects Recently, high-dose chemotherapy with subsequent reinfusion of haematopoietic peripheral blood stem cells (PBSC), or bone marrow has become widespread in the treatment of a variety of solid tumors.
worthy and in some rare cases may even be life-threatening. [2] [3] [4] [5] [6] Side-effects commonly observed in this setting are flushing, abdominal cramping, nausea and vomiting, dyspnea and chest tightness, cough, fever and changes in blood pressure and heart rate 2,7-9 These infusion-related toxicities are supposed to be the result of the volume that is reinfused, the cytoprotectant dimethyl sulfoxide (DMSO) and the cell lysis products of mature granulocytes and erythrocytes. 2, 7 In addition to the clinical presentation, especially the prompt flushing, our observation that at least some of these side-effects can be prevented by the highly selective serotonin receptor (5-HT 3 ) antagonist ondansetron, led to the suspicion that reinfusion of PBSC or bone marrow coincides with infusion of relatively high concentrations of serotonin (5-hydroxytryptamine, 5-HT). This might be caused by platelet lysis or platelet release coinciding with reinfusion, since platelets are the main reservoir for serotonin in the blood. 10 Therefore, parameters of serotonin metabolism were studied before and after reinfusion of PBSC and/or bone marrow.
Patients and methods

Patients
Between May 1994 and January 1996, 25 patients with different solid tumors participating in studies with high-dose chemotherapy followed by reinfusion of either PBSC or PBSC with additional bone marrow, were evaluated after giving informed consent. Patients received various induction regimens, harvest regimens and high-dose chemotherapy regimens, dependent on the primary tumor and ongoing protocols. The study protocols were approved by the Medical Ethical Committee and all patients gave informed consent for participation in the respective studies.
PBSC and bone marrow
The PBSCs were collected from a wide-bore, doublelumen, central venous access catheter. The patients underwent leukapheresis by a continuous-flow blood separator (Cobe Spectra, Lakewood, CO, USA) at the Red Cross Blood Bank. The harvest of PBSC was monitored by the number of nucleated cells ×10 8 /kg and the number of cells bearing the antigen phenotype CD34/kg and colony-forming units granulocyte-macrophage (CFU-GM) ×10 4 /kg body weight in leukapheresis samples. The aimed minimal harvest was 5 × 10 6 /kg body weight CD34 + cells per ablative dose. The PBSCs were reduced in volume and cryopreserved in 10% autologous plasma and 10% DMSO, frozen with a controlled rate freezing and maintained in liquid nitrogen at −180°C.
Bone marrow was harvested from the posterior iliac crest under general analgesia combined with regional anesthesia. The bone marrow harvest was aimed at a minimal yield of 1 × 10 8 nucleated cells/kg body weight. A buffy coat concentrate was cryopreserved using 10% DMSO, frozen at a controlled rate and stored in liquid nitrogen.
Reinfusion
Shortly before reinfusion, the bags with cryopreserved PBSC or bone marrow were rapidly thawed in a waterbath at 37°C and infused unfiltered through a central venous catheter, at a rate of about 50 ml per 5 min. Patients received premedication before reinfusion, consisting of prednisolone 25 mg intravenously (i.v.) and clemastine fumarate 1 mg i.v. at 12 h and 8 h before reinfusion. Fifteen minutes before reinfusion, they again received prednisolone 50 mg i.v. and clemastine fumarate 2 mg, as well as ondansetron 8 mg i.v. Four hours before reinfusion, prehydration with infusion of 1 liter sodium-bicarbonate 1.4% infusion was also started.
Parameters of serotonin metabolism
Parameters of serotonin metabolism were monitored by measuring serotonin levels in platelet-rich plasma before and 1 h post-reinfusion as well as the urinary 24 h excretion of serotonin and 5-hydroxy-indoleacetic acid (5-HIAA) before and after reinfusion of PBSC. 11 In addition, in 17 patients serotonin levels in PBSC were determined, total concentrations as well as the concentrations in cell pellets and supernatant.
For determination of serotonin levels in platelets, venous blood was collected in 10 ml vacutainer tubes (Becton Dickinson, Meylan, France) containing 0.12 ml of 0.34 mol/l EDTA solution and put on ice without delay. Platelet rich plasma was prepared within 1 h after sampling by centrifuging for 30 min at 120 g and 4°C. Na 2 S 2 O 5 and EDTA were added as preservatives to final concentrations of 10 g/l each, and afterwards samples were frozen at −20°C. Platelet-rich plasma was additionally separated into platelet-poor plasma and a pellet by centrifugation as described by Crawford. 12 All samples were analyzed within 1 week after collection. For determination of urinary excretion of serotonin and 5-HIAA, patients collected 24 h urine in brown polypropylene bottles (Sarsted, Numbrecht, Germany), containing 250 mg each of Na 2 S 2 O 5 and EDTA as preservatives. Samples were acidified to pH 4 with acetic acid and then frozen at −20°C. Serotonin levels in PBSC bags, in platelets and in urine were determined by HPLC with fluorometric detection as described by Kwarts et al. 13 Platelet serotonin content, expressed in nmol/10 9 was calculated by dividing the concentration of serotonin in plateletrich plasma by the concentration of platelets in platelet-rich plasma. Urinary 5-HIAA was determined in ether extracts by HPLC with fluorometric detection, essentially described by Rosano et al. 14 On the day of reinfusion, blood platelet counts were performed. In all patients the blood serotonin pool before reinfusion was estimated by multiplying the serotonin level in platelets with the number of platelets and assuming a total blood volume of 5 l. In the 17 patients for whom the bags containing PBSC were tested, the amount of serotonin reinfused was calculated from the volume reinfused and the total serotonin level in the bags. Afterwards, in these patients the amount of reinfused serotonin was related to the estimated blood serotonin pool before reinfusion in order to assess the percentage of increase of total blood serotonin pool.
Statistical analysis
Statistical analysis was performed by using the paired Student's t-test for changes in serotonin metabolism and a P value р0.05 was considered to be significant. Table 1 shows the baseline characteristics of the patients. The 25 patients included received a total of 30 reinfusions of PBSC, which in four cases was combined with reinfusion of bone marrow, according to the ongoing study protocol. The volume reinfused ranged from 180 ml to 817 ml, with a mean (± s.d.) volume of 471 ± 185 ml. Table 2 presents the mean concentrations (±s.d.) of serotonin in platelets as well as the 24-h urinary 5-HIAA levels Table 2 Effects of reinfusion of PBSC or bone marrow on parameters of serotonin metabolism Before mean After mean P value
Results
Serotonin in platelets (nmol/10 9 ) 3.2 ± 1. and serotonin levels before and after reinfusion. On the day of reinfusion, the mean (±s.d.) platelet level was 117 ± 64 × 10 9 /l. Mean total serotonin concentration (±s.d.) in the PBSC bags was 2404 ± 1551 nmol/l (n = 17), whereas the mean serotonin concentration in the supernatant and in the pellets was 635 ± 570 nmol/l (n = 16) and 4271 ± 3991 nmol/l (n = 15), respectively. The mean (±s.d.) total amount of serotonin infused with PBSC was 976 ± 768 nmol.
In all patients, the platelet serotonin was multiplied with the platelet number, resulting in a mean (±s.d.) serotonin level per liter blood of 358 ± 253 nmol. Assuming a blood volume of 5 l, the mean circulating serotonin pool in patients is estimated to be 1790 ± 253 nmol. In the 17 patients for whom the bags were tested, the mean estimated circulating serotonin pool before reinfusion was 1308 ± 697 nmol. In addition, in these patients the amount of serotonin reinfused was divided by the estimated serotonin pool, resulting in a mean increase (±s.d.) of blood serotonin pool after reinfusion of 102 ± 99%.
Discussion
Reinfusion of PBSC or bone marrow is frequently accompanied by side-effects, such as flushing, abdominal cramping, nausea and vomiting, dyspnea and chest tightness, cough, fever and changes in blood pressure and heart rate. 2, [7] [8] [9] In the past, the occurrence of these side-effects has been ascribed to the reinfusion of large graft volumes, cell lysis products and to the amount of the cryoprotectant DMSO. [2] [3] [4] [5] [6] [7] After the introduction of specific serotonin receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting, we observed that fewer side-effects occurred when these drugs were given before reinfusion of PBSC. That, and the clinical spectrum of symptoms led to the assumption that serotonin metabolism was influenced by reinfusion of PBSC or bone marrow. Therefore, we studied the peripheral serotonin metabolism before and after reinfusion.
The bags with PBSC contained substantial amounts of serotonin, of which the majority appeared to be plateletconfined. After reinfusion of PBSC, an increase in the level of serotonin in platelets was observed. This rise in platelet serotonin is thought to be the result of the amount of free serotonin reinfused. However, it is also possible that reinfusion is associated with platelet lysis, giving rise to release of platelet-confined serotonin. Another explanation for the increase in platelet serotonin content might be a change in the composition of the total platelet pool after reinfusion. As the serotonin concentration in the cell pellets of the bags was considerable, reinfusion might occur with platelets with a higher serotonin content than that of the circulating platelets, resulting in an increase of average platelet serotonin content. The symptoms coinciding with the reinfusion thus can be the result of the amount of free serotonin reinfused.
In the body, free serotonin is rapidly cleared from the circulation. This rapid disappearance of serotonin following i.v. injection is mainly due to uptake in liver cells or in endothelial cells of the pulmonary circulation, where it subsequently is metabolized to 5-HIAA. 10 Despite the fact that up to 90% of all free serotonin can be removed in a single passage, 10 plasma serotonin load can be substantial. Platelets are supposed to act as scavengers for extracellular serotonin because of their efficient serotonin uptake and storage, which previously appeared to be related to free serotonin levels. 12, 15 Platelets do not show serotonin synthesis or turnover themselves. 16 However, the uptake of serotonin in platelets is relatively slow compared to the rapid uptake in endothelial cells, but after many circulating times the platelet uptake will significantly contribute to the overall removal. 10 We determined platelet serotonin concentrations 1 h after reinfusion. It is not very likely that reinfusion of PBSC or bone marrow influences the gastrointestinal synthesis or release of serotonin, or the clearance of endogenously released serotonin. Normally, the majority of the stored serotonin remains in platelets during their entire life span and the half-life of platelet serotonin is reflected by platelet survival with an average of about 3-4 days. [16] [17] [18] Also it is unlikely that either volume effects or serotonin releasing effects contributed to the observed rise in platelet serotonin content, as these events were not seen during infusion of platinum and saline. 19 In this study, the mean total amount of serotonin infused with PBSC is about 976 ± 768 nmol, whereas the mean estimated blood serotonin pool in the patients of whom the bags were tested is about 1308 ± 697 nmol. Reinfusion of PBSC or bone marrow therefore gives a substantial increase in total blood serotonin and thereby in platelet serotonin content. We found that in the patient group total blood serotonin was low compared to healthy adults. In healthy adults, the platelet count is about 200 × 10 9 /l, and with a blood volume of about 5 l, this gives a total of 1000 × 10 9 platelets. This combined with the normal platelet serotonin content of about 3 nmol ×10 9 platelets/l, 18 the total blood serotonin pool in healthy adults is estimated to be 3000 nmol. This is considerably higher than the mean estimated blood serotonin pool in all patients included in this study, of about 1790 ± 1265 nmol. This observation confirms the data of Schröder et al 19 on depletion of blood serotonin after chemotherapy.
The increase in serotonin in platelets did not coincide with an increase in urinary 5-HIAA excretion. This can be explained on the basis of pool size calculations. The mean daily urinary 5-HIAA excretion, which is mainly derived from serotonin turnover in enterochromaffin cells of the gastrointestinal tract, 20 is about 16.5 mol. 18 In addition, under normal conditions platelet turnover in the platelet serotonin pool produces 1.2 mol 5-HIAA daily. 18 The reinfusion of PBSC, coinciding with infusion of about 1000 nmol serotonin, induces an additional 1 mol 5-HIAA/24 h excretion after metabolization. On top of the normal excretion of about 16.5 mol/24 h, this surplus accounts for an increase of only 6% of normal 5-HIAA excretion. Daily variability in 5-HIAA excretion may amount to up to 30%, 21 partly due to dietary influences of serotonin rich food. Thus, the surplus caused by reinfusion in a 24 h collection will not be detectable. Previously, we found platelet serotonin content to be a more sensitive marker for detecting an endogenous serotonin load than urinary 5-HIAA excretion in carcinoids that produce only small amounts of serotonin. 18 Previously, no intravenous serotonin loading studies have been described. However, in the past, the effects of an oral, dietary serotonin load on parameters of peripheral serotonin metabolism have been studied. 17, 22 Specifically, short-term consumption of serotonin-rich foods did not affect platelet serotonin content and increased urinary 5-HIAA excretion within 2-4 h after intake. 22 However, after a long-term oral serotonin ingestion (160 mg (0.9 mmol) per day for 18 days), both increases in platelet serotonin content and urinary 5-HIAA excretion were observed. 17 The observation that serotonin levels in platelets increase after reinfusion is not in conflict with the efficacy of ondansetron in mitigating side-effects, because ondansetron is only a 5HT 3 receptor blocker and does not influence release, uptake and storage of serotonin. 19 In conclusion, reinfusion of PBSC or bone marrow coincides with substantial infusion of serotonin, which affects peripheral serotonin metabolism. This infusion of serotonin can, at least partially, explain the accompanying side-effects of reinfusion of PBSC or bone marrow. Therefore, patients might benefit from pre-medication with serotonin receptor blockers for this procedure.
